Search Results 211-220 of 16875 for Antagonist
Preclinical studies in drug therapies for polycystic kidney disease, such as octreotide and vasopressin antagonists. Finding effective therapies for ...
The study focused on histamine 2 receptor antagonists. The researchers found no significant risk for people taking over-the-counter antihistamine drugs ...
... antagonist (adalimumab subcutaneously [SC]), and an immunomodulator (oral methotrexate) on endoscopic remission in participants with newly-diagnosed Crohn's ...
The goal of this clinical study is to determine the safety and efficacy of VT-464, a lyase-selective inhibitor of CYP17 and an androgen receptor antagonist ...
As luck would have it, the molecule had a natural inhibitor, aptly named the IL-1 receptor antagonist (IL-1Ra), that could form the basis of the first gene ...
... antagonists. His translational research aims to accelerate developing and implementing disease-modifying therapies for inherited kidney diseases. Gene ...
Gattone led to several clinical trials of tolvaptan, a V2 receptor antagonist. These trials include a large phase 3:4 clinical trial and have already led to ...
Subjects taking H2-antagonists or proton pump inhibitors and unwilling to discontinue therapy for 1 week before and 2 weeks following enrollment. QTc ...
... antagonists are allowed if one of the following criteria is met at the screening visit: A minimum of 8 weeks of stable treatment (12 weeks of stable ...
Secondary ICH related to known causes (e.g., trauma, aneurysm, arteriovenous malformation (AVM), oral anticoagulant use (vitamin K antagonists or novel oral ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your donation powers the future of medicine and helps save lives.